Merck applies for expanded Gardasil use, Glaxo says Cervarix offers protection for over 5 years

Share this article:
Merck said it has applied with the FDA for expanded approval of its Gardasil vaccine to help prevent vaginal and vulvar cancers. Gardasil protects patients against four types of the sexually transmitted human papillomavirus. Two types of the virus are responsible for about 70% of cervical cancer cases, while the other two types are responsible for about 90% of genital wart cases. However, all four types of the HPV virus account for 35% to 50% of all low-grade cervical, vulvar and vaginal lesions, Merck said. Merck expects the FDA to determine whether it will accept Merck’s application for review within the next 60 days. If the agency reviews the application, a decision could come within 10 months of the filing date. Gardasil received its first approval for cervical cancer in June 2006. Meanwhile, GlaxoSmithKline said that its developmental cervical cancer vaccine Cervarix has been found to prevent women from developing pre-cancerous lesions caused by the two main cancer-causing viruses for five-and-a-half years. Glaxo claimed the results demonstrate the longest duration of protection seen in any cervical cancer vaccine trial reported to date. In new data presented at the American Association for Cancer Research, Cervarix showed 68% vaccine efficacy against pre-cancerous lesions and 38% efficacy against abnormal Pap smears, regardless of the type of cancer-causing virus detected, Glaxo said The data also provided further evidence of cross-protection against infection with the less common cancer causing viruses that extended for up to 5.5 years. Cervarix is waiting for marketing approval in US. If approved and launched, it will compete against Gardasil. Gardasil has gained an early advantage as the only cervical cancer vaccine on the market. Analysts have given Gardasil the edge but GlaxoSmithKline has countered that Cervarix is more powerful. The drugmaker is funding an unusual head-to-head study to try to prove that Cervarix is more potent than Gardasil. Results of the study are anticipated by January 2008.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...